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Decamethylcyclopentasiloxane (D5) is a low-molecular-weight cyclic siloxane used primarily as an in-
termediate in the production of several widely-used industrial and consumer products and intentionally
added to consumer products, personal products and some dry cleaning solvents. The global use requires
consideration of consumer use information and risk assessment requirements from various sources and
authoritative bodies. A global “harmonized” risk assessment was conducted to meet requirements for
substance-speciﬁc risk assessments conducted by regulatory agencies such as USEPA's Integrated Risk
Information System (IRIS), Health Canada and various independent scientiﬁc committees of the Euro-
pean Commission, as well as provide guidance for chemical safety assessments under REACH in Europe,
and other relevant authoritative bodies. This risk assessment incorporates global exposure information
combined with a Monte Carlo analysis to determine the most signiﬁcant routes of exposure, utilization of
a multi-species, multi-route physiologically based pharmacokinetic (PBPK) model to estimate internal
dose metrics, benchmark modeling to determine a point of departure (POD), and a margin of safety
(MOS) evaluation to compare the estimates of intake with the POD. Because of the speciﬁc pharmaco-
kinetic behaviors of D5 including high lipophilicity, high volatility with low blood-to-air partition co-
efﬁcients and extensive metabolic clearance that regulate tissue dose after exposure, the use of a PBPK
model was essential to provide a comparison of a dose metric that reﬂects these processes. The char-
acterization of the potential for adverse effects after exposure to D5 using a MOS approach based on an
internal dose metric removes the subjective application of uncertainty factors that may be applied across
various regulatory agencies and allows examination of the differences between internal dose metrics
associated with exposure and those associated with adverse effects.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Decamethylcyclopentasiloxane (D5), a low-molecular-weight
cyclic siloxane, is primarily used as an intermediate in the pro-
duction of some widely-used industrial and consumer products
and intentionally added to personal care products, cosmetics and in
GreenEarth solvent used in dry cleaning. Consequently, its wide-
spread use can result in the potential for exposure in workers
(occupational exposure), consumers and the general public. TheFranzen), cvanlandingham@
vironcorp.com (T. Greene),
environcorp.com (R. Gentry).
Inc. This is an open access article upotential for human exposure has resulted in the identiﬁcation of
D5 as a compound of interest to various authoritative bodies and
scientiﬁc committees worldwide (e.g., United States Environmental
Protection Agency (USEPA), Health Canada, and the Scientiﬁc
Committee on Consumer Safety (SCCS)). However, the methods
used, endpoints relied upon, and assumptions applied in assessing
the potential for human risk across assessments have varied.
Rather than attempt to account for or justify differences in ap-
proaches and assumptions, a “globally harmonized” risk assess-
ment was conducted that addresses the requirements for
substance-speciﬁc risk assessments conducted by these various
global agencies and committees. Based on the potential for expo-
sure, this harmonized human health risk assessment considered
the potential hazard from exposure to D5 in workers, consumers,
and the general public who may be exposed to D5 either in thender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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to D5 released to the environment.
In addition to consideration of the available exposure and
toxicity data that are typically used in a standard risk assessment,
an integrated multi-route multi-species physiologically based
pharmacokinetic (PBPK) model for both the rat and the humanwas
incorporated (McMullin et al., 2015). Rather than relying only on
external air or dietary concentrations, the doseeresponse and
exposure assessments were conducted using both an external
exposure concentration and an internal dose metric estimated us-
ing the PBPK model. D5 is a volatile cyclic methyl siloxane that has
speciﬁc pharmacokinetic behaviors including high lipophilicity,
high volatility with low blood-to air-partition coefﬁcients and
extensive hepatic metabolism (Battelle Northwest Toxicology,
2001; Dow Corning Corporation, 2003; Reddy et al., 2008; Xu and
Kropscott, 2007). These properties lead to rapid systemic clear-
ance of the parent material in the blood by exhalation and meta-
bolism following inhalation, dermal and oral exposure. Because
these multiple pharmacokinetic processes regulate tissue dose
following D5 exposure, the use of a PBPK model in the risk
assessment allows for the development of internal dose metrics for
use in doseeresponse modeling and exposure assessment that
reﬂect these processes.
The results of a risk assessment or the risk characterization are
typically numerical estimates of risk or hazard that are derived by
comparing the estimated exposure or intake with some measure of
a toxicity value, i.e., the point of departure (POD) adjusted by un-
certainty factors to reﬂect interspecies and intraspecies variability.
However, when multiple populations are to be evaluated globally
by multiple regulatory agencies, rather than decide appropriate
uncertainty factors a priori, Margins of Safety (MOS) were deter-
mined for this assessment by comparing the estimated POD to the
estimated intake. In addition to using this comparison for the MOS,
both the POD and the estimated intake were expressed as the in-
ternal dose-metric using the results of a PBPK model, which in-
corporates species differences in physiology and pharmacokinetics.
The magnitude of the MOS was then evaluated for the different
potentially exposed populations (workers, consumers and the
general public) in the context of what would be deemed an
acceptable margin by various global regulatory agencies.
2. Methods
2.1. Hazard identiﬁcation
The available toxicological literature (Dekant and Klaunig this
issue) as well as the application of studies in other hazard assess-
ments conducted worldwide were considered (Environmental
Control Center Co. 2011; Health Canada, 1994, 2008; REACH,
2011; REACH Registration Dossier, 2011; SCCS, 2010). All of the
available toxicological literature was used in drawing conclusions
regarding the potential for hazard following exposure to D5 and
determine which endpoints were the most sensitive or were
observed following exposure to the lowest concentrations.
2.2. Dose-response assessment
Dose-response assessments have been conducted for D5 by
Health Canada (2008), the European Commission's Scientiﬁc
Committee on Consumer Safety (SCCS, 2010) and under REACH
(2011). The methodologies used globally are all similar in that
they determine a Point of Departure (POD) and apply a form of
safety/uncertainty factors to the POD to determine an acceptable
dose/concentration. However, differences do remain due to the
subjectivity and variability in the choice and application ofuncertainty factors, not only in different countries, but also in
different regulatory agencies within each country. For this assess-
ment, rather than attempting to derive factors that may be used by
the various regulatory agencies worldwide to adjust the POD for
low-dose extrapolation, a comparison was made between the in-
ternal dose metric associated with the lower bound on the
benchmark dose (BMDL) and the internal dose metric estimated for
each relevant exposure scenario.
2.2.1. Estimation of the human equivalent concentration
When data from animal studies are extrapolated to humans to
provide estimates of lifetime cancer risks, potential differences in
pharmacokinetics (absorption, distribution, metabolism and
excretion) and pharmacodynamics (sensitivity) between the ani-
mal species and humans should be considered in the estimation of
human equivalent doses. A multi-route, multi-species PBPK model
(McMullin et al., 2015) was used to estimate a internal dose metric
associated with each of the animal exposure concentrations for use
in doseeresponse modeling. For this assessment, the internal dose
metric relied upon is the Area Under the Curve (AUC) of free D5
(parent compound) in the blood. This assumption is justiﬁed based
on the pharmacokinetic behavior and fate of D5
Upon absorption, D5 is either exhaled as parent D5 or undergoes
hepatic metabolism primarily to water soluble silanol metabolites
that are rapidly removed from circulation and excreted by the
kidney into the urine. A more polar yet still lipophilic metabolite
(hydroxylated D5) was also detected in fat and feces. This metab-
olite partitions primarily into the fat tissue and as it partitions back
out into the blood it is further metabolized to the same water
soluble silanol metabolites (that are rapidly eliminated) or is
eliminated through enterohepatic circulation in the feces
(Andersen et al., 2001; Reddy et al., 2003, 2007). Due to the un-
certainty in the mode of action for the uterine tumor endpoint
relied upon this assessment, the choice of using the free concen-
tration of D5 in the blood is the most reasonable moiety available
for distribution to target tissues. The free concentration of parent
D5 in blood also provides a reasonable surrogate for target tissue
dose because it partitions fairly equally between blood and tissues,
with the exception of the fat tissue (McMullin et al., 2015). In
addition, the use of an AUC as themost appropriate dose metric has
been considered to be an appropriate dose metric for assessment to
health risk related to lifetime exposure of systemically acting
chemicals (USEPA, 2006a).
2.2.2. Estimation of point of departure
In conducting the doseeresponse modeling, two dose-metrics
were considered. The ﬁrst was the external animal exposure con-
centration in ppm adjusted from 6 hours per day and 5 days per
week to continuous exposure. The second was the PBPK-derived
animal internal dose metric (AUCs) for each exposure concentra-
tion. If there were no survival differences in treated animals, the
doseeresponsemodeling was conducted using USEPA's Benchmark
Dose Software (BMDS) Version 2.3.1, an available free software
program providing all of the typical models applied in BMD
modeling, and the model with the best ﬁt was chosen. Best ﬁt of a
model to the data was determined using three different goodness-
of-ﬁt criteria: the Akaike Information Criteria (AIC), a p-value, and
the scaled residual of interest.
The AIC is a function of the maximum log-likelihood and the
number of parameters in the model. It can be used to compare the
ﬁt of different models for a single dataset and the smallest AIC in-
dicates the “best” ﬁt. The p-value is from a Chi-Square goodness-of-
ﬁt test and has values between 0 and 1. A minimum value of 0.1 is
needed for an adequate ﬁt of the model to the data and the larger
the value (e.g. closer to 1), the better the ﬁt. The scaled residual of
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closest to the BMD and indicates howwell the model ﬁts the data at
that point on the doseeresponse curve. A zero is the ideal scaled
residual with an absolute value of 2 or greater indicating an un-
acceptable ﬁt, so a scaled residual with a smaller value indicates a
better ﬁt.
2.3. Exposure assessment
Estimates of exposure were based on measurements or models
of existing conditions for the potentially exposed populations
(workers, consumers and the general public).
Several populations that might be exposed to D5 through
various pathways included: occupational exposure to workers,
consumers, and the general public. Occupational workers consist of
persons who work in the production of D5, in the formulation of
this material into personal care products, individuals in the dry
cleaning industry that use GreenEarth solvent, or in the use of these
products in professional settings, such as beauticians and barbers.
Primary exposure to D5 in the occupational setting was considered
to occur through the inhalation route, with beauticians and barbers
also being exposed through the dermal route.
Consumers consist of persons who use personal care products,
including antiperspirant/deodorants (AP/Ds) (aerosols, solids, and
roll-ons) and hair care/skin care (HC/SC) products (i.e., shampoo,
conditioners, hair spray/hand or body lotion, sunscreen, mascara,
lipstick). While potential exposure to consumer products occurs by
all routes of exposure (dermal, oral or inhalation), the primary
exposure would be through the dermal route. Dermal exposure
occurs through the intentional, direct application of the product to
the skin, with potential for inhalation exposure as the product
residue on the skin volatilizes.
General public consists of persons who may be exposed to
ambient levels of D5 released to the environment during
manufacturing activities and to predicted levels of D5 in soil, water,
and food such as meat, vegetables, milk and breast milk. The pri-
mary routes of exposure for the general public considered were
inhalation of D5 in both indoor and outdoor air and oral exposure
from the consumption of water, ﬁsh, vegetables, meat, milk, soil,
anti-foam in food, and breast milk containing D5. In general,
monitoring programs have not been conducted to detect D5 in food
and water and it is uncertain if D5 is present in any of the foods
mentioned above or in drinking water.
2.3.1. Monte Carlo Analysis
Because of the large number of potential exposure pathways for
the consumer and the general public, a Monte Carlo probabilistic
analysis was conducted to prioritize those scenarios that would
potentially result in the greatest exposure. Those scenarios with the
highest potential for large exposure were included in the PBPK
analysis. This involved the various exposure scenarios for dermal
uptake from contact with the skin, inhalation from ambient air, or
oral consumption of environmental media (water) or consumer/
food products and identiﬁes those pathways providing the greatest
contribution of potential exposure. As the only exposure scenarios
considered for the worker receptors were inhalation and dermal
contact for barbers and beauticians, Monte Carlo analysis was not
conducted for these receptors and the exposure for occupational
receptors was evaluated directly by the PBPK analysis.
The Monte Carlo analysis produced an estimate of the intake of
D5 in mg/kg of body weight (bw)/day from each consumer item and
from general sources (air, water, food and soil) using distributions
for the parameters in order to prioritize the exposure to consumer
products and to general sources; as well as assist in the identiﬁ-
cation of Consumer and General Public exposure pathways thatprovided the greatest potential for exposure to D5. Only those
exposure pathways that were associated with speciﬁc product us-
age that had the largest estimates for intake based on the results of
the Monte Carlo analysis were then used with the PBPK model to
obtain an estimate of the internal dose for comparison to the in-
ternal dose associated with the POD.
TheMonte-Carlo-based probabilistic assessment for D5 included
the following age-dependent and exposure-route-dependent sce-
narios with each product being evaluated independently:
Children.
 Dermal route: body lotion, conditioner (leave in), conditioner
(rinse off), diaper cream, shampoo, soothing vapor, spray
detangler, and sunscreen.
 Ingestion route: antifoam, baby bottle nipple, ﬁsh (general
population), ﬁsh (subsistence population), breast milk, leafy
vegetables (greens), meat, cow's milk, paciﬁer, root vegetables,
sipper tube, soil, straws, water, and over-the-counter (OTC) anti-
gas medication.
 Inhalation route: indoor air, outdoor air, soothing vapor.
Adults.
 Dermal route: after shave, body lotion, conditioner (leave in),
conditioner (rinse off), foundation, hair spray, mascara, mois-
turizer, nail care, shampoo, antiperspirant (gel/solid, roll-on and
spray), soothing vapor, sunscreen, and under-eye cream.
 Ingestion route: antifoam, ﬁsh (general population), ﬁsh (sub-
sistence population), leafy vegetables (greens), lipstick, meat,
milk, root crops, soil, and water, as well as OTC antigas
medication.
 Inhalation route: indoor air, outdoor air, and soothing vapor.
Separate route-speciﬁc estimates were made for males or fe-
males for the following subpopulation: children 0e6 months, 6
months-4 years, 4e11 years, teens from 12 to 19 years, and adults
20e59 years and 60 þ years. In addition combined males and fe-
males for the ages of 0e6 months, 7e11 months and 1e2 years was
stratiﬁed by breastfed versus non-breastfed. A non-gender-speciﬁc
population, children ages 2e4 years were also considered.
Input parameter distribution values used for each of the vari-
ables presented below in the dermal, inhalation and oral equations
are summarized in Supplementary Tables S-1 through S-5 and are
based on a conservative choice from all of the relevant data avail-
able. For each product evaluated, the intake from each pathwaywas
estimated with the results provided in units of mg D5/kg bw/day.
Themean reported intake for each pathwaywithin each gender age
group were then compared to evaluate which of the exposure
pathways resulted in the higher estimates of intake and which
would be considered to have a negligible contribution to overall
intake.
A second Monte Carlo analysis was subsequently performed to
estimate the total oral intake of D5 per day (mg/kg/day) for use in
estimating internal dose-metrics using the PBPK model. For this
analysis the estimated intakes for each oral exposure scenario
(water, food, antifoam, soil and lipstick) were summed. Bioavail-
ability factors were not considered for this analysis in the estimates
of intake, as the PBPK model accounts for the bioavailability by the
oral route. Because the PBPK model is only an adult model, oral
consumption for childrenwas not considered in the PBPKmodeling
analysis.
2.3.1.1. Dermal. For dermal exposures, the following general
equationwas used, with speciﬁc parameters used for each exposure
scenario documented in the supplemental material.
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BW
(1)
where:
AppR ¼ application rate of the product in grams per application
(grams per application)
Freq ¼ frequency of application (applications per day)
Conc ¼ concentration of D5 in the product as a percentage (%)
Abs ¼ absorption fraction (fraction)
KF ¼ kinetic factor (fraction)
Conv ¼ conversion factor from g to mg (1000)
BW ¼ body weight (kg)
Application rates of D5 from the use of consumer products are
typically provided as either grams/application (AppR) or grams per
day (GD). If the application rate (AppR) is provided in units of
grams/day, the equation is modiﬁed because the usage for a
product, the Freq is assumed to be once per day, effectively
replacing the AppR  Freq variables with GD.
Estimating exposure to D5 from the use of hair care products
requires modiﬁcation to Equation (1) to include parameters to
characterize the application of the product (e.g., shampoo, condi-
tioner, etc.), as well as the potential removal of product due to
rinsing.
Intakeðmg=kg=dayÞ
¼ AppR  Freq Conv Conc Abs KF  Res Dep
BW
(2)
where:
AppR ¼ application rate of the product in grams per application
(grams per application)
Freq ¼ frequency of application (applications per day)
Conv ¼ conversion factor from g to mg (1000)
Conc ¼ concentration of D5 in the product (%)
Abs ¼ absorption fraction (fraction)
KF ¼ kinetic factor (fraction)
Res ¼ product (residue) left on hands and scalp after rinsing
(fraction)
Dep ¼ fraction deposited on hands and scalp versus the hair
(fraction)
BW ¼ body weight (kg)
Body weight distributions for males and females in the Euro-
pean nations that were considered are presented in Supplementary
Table S-6. The mean values were obtained from the ECETOC
Exposure Factors Sourcebook (ECETOC, 2001) while the standard
deviations were taken from Eurostat (2002). For the United States,
mean body weights for men, women and children from the Na-
tional Health and Nutrition Examination Study (NHANES) for the
years 2007/2008 and 2009/2010 were used. These estimates,
including the minimum andmaximum body weights are presented
in Supplementary Table S-7. The results from the NHANES 2007 to
2010 were considered as most suitable for use in this assessment
because they represent the most current values available. The
distributions of adult body weight values provided in the NHANES
data encompass the default body weight values used globally for
risk assessment. Additionally, the distribution of body weights
assumed in the Monte Carlo analysis from the NHANES data en-
compasses the body weights available for other populations.One of the key parameters for estimating potential dermal
exposure is the skin surface area to which a product is applied.
Information on the receptor skin surface area for occupational
workers was obtained from the Exposure Factors Handbook
(USEPA, 2011) and is summarized in Supplementary Table S-8.
Since the majority of application rates were deﬁned for the US
population, use of the USEPA surface areas should provide the
correct proportioning of product to surface area. For the SC prod-
ucts, the deposition fraction (Dep) or the fraction of product that is
potentially available for absorption was assumed to be 1 (100%).
However, for some of the HC products, especially the leave-on HC
products, only a small fraction of the product is deposited on the
scalp and available to be absorbed into systemic circulation. For
these types of HC products a deposition fraction of 0.05 (5%) was
used. This value was estimated based on the ratio of the surface
area of the scalp to that of the hair on the head (<0.05). Based on the
average length of one hair of 10 cm for men and 15 cm for women
(ICRP, 2002), an average diameter of each hair of 60 microns
(Kalopissis, 1986), and an average of 115000 hairs on the scalp
(Kalopissis, 1986), the surface area of hair over which a HC product
could be distributed was approximately 22000 cm2 for men and
33000 cm2 for women. For the remaining HC and other personal
care products, a deposition fraction of 1 (100%) was assumed.
Residue fractions were used in the Monte Carlo analysis to ac-
count for the amount of a product that could be deposited on the
skin. These residue fractions do not take into consideration the
volatility of D5. Residue fractions were assumed to be 1 (100%) for
all HC/SC products, with the exception of any rinse-off products
such as shampoo and rinse-off conditioner. Shampoos and rinse-off
conditioners were assumed to leave only a fraction of the product
as residue on the skin. Maxim (1998) reported that the product
remaining after the application of a rinse-off product, was typically
small, ranging from 0.5% to 1.5% based on interviewwith personnel
from the HC industry. A residue fraction of 0.01 (1%) was used for
shampoos and rinse-off conditioners. This residue fraction is
consistent with the fractions proposed by the American Cleaning
Institute (SDA, 2005) for screening dermal exposure to consumer
products in Europe and residue studies conducted in similar
products (USEPA, 1997; USFDA, 1982; USFDA, 1978). For the
remaining products, a conservative residue fraction of 1 (100%) was
assumed.
A study performed by Reddy et al. (2007), indicated that 83% of
the dermally applied D5 (0.94 g for women, 1.34 g for men) that
reaches the systemic circulation was eliminated by exhalation
within 24 hours. The 17% (0.17) that reached the systemic circula-
tion and was not exhaled was considered representative of the
kinetic factor. A value of 0.0004 (0.04%) was used as the dermal
absorption factor as described in Jovanovic et al. (2008). The 0.045
was determined by the average amount of neat D5 absorbed after
24 hours of exposure to cadaver skin in vitro. Both the kinetic
fraction and the absorption fraction were used in the evaluation of
dermal exposure to consumer products.
The application frequencies for consumer products containing
D5 used in the Monte Carlo analysis are presented in
Supplementary Tables S-1 through S-4 and include information
from multiple sources (Hall et al., 2007, 2011; Horii and Kannan,
2008; Health Canada, 2008; Loretz et al., 2005, 2006, 2008;
Maxim, 1998; McNamara et al., 2007). The application rate used
for the consumer products was the number of grams of product
applied each time (grams/application) or over the entire day
(grams/day). In this case, the maximum amount of the product
applied during the daywas indicated and, therefore, the application
frequency was assumed to be once per day, although some of these
products could be applied multiple times per day. For most of the
products the use of grams per day was sufﬁcient since the products
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were exceptions such as lipstick (2.35 times during the day (Loretz
et al., 2005)) and there were products for which an application rate
in grams per day was not available. In these instances the grams per
application and application frequencies were obtained fromMaxim
(1998).
A uniform distribution over the ranges of percent of D5 in
various consumer products (Supplementary Table S-9) was used as
the amount of D5 in consumer products for the Monte Carlo anal-
ysis. The data provided from Johnson et al. (2011) was typically
used as these were the most recent published data and in general
the ranges encompassed the reported concentrations of D5 from
other sources (Boehmer and Gerhards, 2003; COLIPA report pre-
2000; Horii and Kannan, 2008; Maxim, 1998; Wang et al., 2009).F2.3.1.2. Inhalation. For the majority of the exposure scenarios that
present the potential for exposure to D5 via inhalation, the
following general equation can be used:
Intakeðmg=kg=dayÞ ¼ Conc  Conv BR KF
BW
(3)
where:
Conc ¼ concentration of D5 in the air (mg/m3)
Conv ¼ conversion factor from mg to mg (1/1000)
BR ¼ breathing rate (m3/day)
KF ¼ kinetic factor (fraction)
BW ¼ body weight (kg)
For the evaluation of inhalation due to volatilization of D5
following the application of soothing vapor, the following equation
must be used:
Intakeðmg=kg=dayÞ ¼ AppR  Freq Conv  Conc FV  BR K
BW  Room
(4)
where:
AppR ¼ application rate of soothing vapor in grams per appli-
cation (grams per application)
Freq ¼ frequency of soothing vapor use (applications per day)
Conv ¼ conversion factor from g to mg (1000)
Conc ¼ concentration of D5 in soothing vapor (%)
FV ¼ fraction of product volatizing (fraction)
BR ¼ breathing rate (m3/day)
KF ¼ kinetic factor (fraction)
BW ¼ body weight (kg)
Room ¼ area of the room in cubic meters (m3)
Body weight distributions were assumed to be the same for all
exposure routes and detailed description of bodyweight data relied
upon has been provided previously in section 2.3.1. Inhalation rates
used in the Monte Carlo analysis were obtained from USEPA (2011)
and are provided in Supplementary Table S-10.
2.3.1.2.1. General public. Indoor air concentrations used for the
Monte Carlo analysis were derived from the NYIEQ (2005) assess-
ment. NYIEQ (2005) reported a median D5 concentration in indoor
air of 34.5 mg/m3 with a range of 2.3e1560 mg/m3. These data were
relied upon to determine a triangular distribution using themedian
value of 34.5 mg/m3 as the most likely value with a minimum of
0.05 mg/m3 and a maximum of 1560 mg/m3. This distribution in-
cludes the ranges of indoor air concentrations seen in other studies
(Hodgson and Levin, 2003; Norden, 2005; Shields et al., 1996; Wuet al., 2011; Yucuis et al., 2013).
For the outdoor air concentrations used in the Monte Carlo
analysis, values from all the available studies that reported outdoor
air concentrations were combined to determine a lognormal dis-
tributionwith a mean of 1.4 mg/m3 and a standard deviation of 8.34
(Boehmer et al., 2001; Kaj et al., 2005; Norden, 2005; Shields et al.,
1996; Yucuis et al., 2013). The distribution was truncated at 20 mg/
m3, the largest value reported.2.3.1.3. Ingestion. Intake of D5 for ingestion scenarios (e.g., inges-
tion of water, soil, ﬁsh, and other food, OTC anti-gas medication,
etc.) was determined using the following equations:
For water or soil:
Intakeðmg=kg=dayÞ ¼ Amt  Conc Conv Bio
BW
(5)
where:
Amt ¼ amount consumed per day (L/day or mg/day)
Conc ¼ concentration of D5 in the product (mg/L or mg/kg)
Conv ¼ conversion factor (for soil from mg to mg in conc and mg
to kg in amt (1/1000000) or for water the conv is 1)
Bio ¼ bioavailability fraction
BW ¼ body weight (kg)
For intake of D5 contained in food:
Intakeðmg=kg=dayÞ ¼ Amt  Conc Conv Bio (6)
where:
Amt ¼ amount consumed (g/kg BW/day)
Conc ¼ concentration of D5 in the food (mg/kg)
Conv ¼ conversion factor from g to kg (1/1000)
Bio ¼ bioavailability fraction
BW ¼ body weight (kg)
For intake of D5 contained in ﬁsh by a subsistence ﬁsherman:
Intakeðmg=kg=dayÞ ¼ Amt  Conc Conv Bio
BW
(7)
where:
Amt ¼ amount consumed per day (g/day)
Conc ¼ concentration of D5 in the ﬁsh (mg/kg)
Conv ¼ conversion factor (g to kg (1/1000)
Bio ¼ bioavailability fraction
BW ¼ body weight (kg)
For intake of OTC medications:
Intakeðmg=kg=dayÞ ¼ Amt  Freq Conc Conv Bio
BW
(8)
where:
Amt ¼ amount consumed per use (g)
Freq ¼ frequency of use (times/day)
Conc ¼ concentration of D5 in the product (mg/g)
Conv ¼ conversion factor (mg to mg (1/1000)
Bio ¼ bioavailability fraction
BW ¼ body weight (kg)
Intakes due to the ingestion of antifoam present in processed
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alternate ingestion equations. The antifoam equation considers
howmuch food is consumed per day as well as the percentage that
contains antifoam.
Intakeðmg=kg=dayÞ ¼ Amt  AF  Conc Frac Conv Bio
(9)
where:
Amt ¼ amount of food consumed (g/kg BW/day)
AF ¼ Fraction of food that contains antifoam (assuming 50%)
Conc ¼ concentration of antifoam in food (mg/kg)
Frac ¼ fraction of D5 in the antifoam
Conv ¼ conversion factor from g to kg (1/1000)
Bio ¼ bioavailability fraction
For lipstick, multiple applications could be possible during a day
so the equation was adjusted to account for that difference.
Intakeðmg=kg=dayÞ ¼ Amt  Conc Freq Bio
BW
(10)
where:
Amt ¼ amount of lipstick (g/application)
Conc ¼ concentration of D5 in the product (mg/g)
Freq ¼ frequency of usage (applications/day)
Bio ¼ bioavailability fraction
BW ¼ body weight (kg)
Intakes due to the use of baby bottle nipples, paciﬁers, and
sipper tubes were calculated using the ingestion equations as
presented below:
Intakeðmg=kg=dayÞ ¼Wgt  ConcMF  Conv Bio
BW
(11)
where:
Wgt ¼ weight of product (grams)
Conc ¼ concentration of D5 in the product (mg/g)
MF ¼ the fraction of D5 in the product that can migrate per day
(%)
Conv ¼ conversion factor from g to kg (1/1000)
Bio ¼ bioavailability fraction
BW ¼ body weight (kg)
The migration fraction (MF) is an estimate of the amount of D5
that can migrate out of the nipple, paciﬁers, and sipper tubes into
formula, milk, salvia, or other mediawith which they are in contact.
Themigration amount used here is assumed to be a per day amount
but there is little evidence that this amount could be repeatedly
extracted from the product or that a new product would be used
each day, so this is a very conservative estimate of the daily
exposure.
A migration factor of 0.0046% per day was used for the amount
of D5 that could migrate from baby bottle nipples, paciﬁers, sipper
tubes and straws based on results from an experiment on the
migration of siloxanes from silicone rubber products into milk,
formula and liquid dietary simulants (Zhang et al., 2012). This study
had two purposes: 1) to determine the concentrations of siloxanes
in silicone products, including silicone nipples and silicone cook-
ware and 2) to determine the potential migration of siloxanes from
products to milk, formula, and liquid simulants. Concentrations ofD5 determined in silicone nipples ranged from 0.5 to 269 mg/g of
product with a median value of 4 mg/g. Due to the irregular shape of
silicone nipples, the authors noted difﬁculty in conducting migra-
tion tests with nipples; and silicone plaques from bakeware were
determined to be good surrogates for silicone nipples. Therefore,
the migration tests were performed using silicone cake pans, with
an average D5 concentration of 3451 mg/kg, as surrogates for sili-
cone nipples. After 24 hours, only trace amounts of D5 were
detected that had migrated from the silicone cake pans into the
milk or formula, indicating insigniﬁcant migration of the siloxanes
to milk or infant formula. Using the concentration of D5 in the
product tested (3451mg/kg), the amount of the product placed into
solution (2 g) and the amount of solution tested for D5 (10 ml), a
conservative estimate of the fraction of migration of D5 is 0.000046.
This was considered a conservative assumption, as it assumes that
the amount of D5 that could migrate out of the product per day
(baby bottle nipple, paciﬁer, etc.) can continue for an unlimited
duration. However, the amount available for migration from the
product would be limited, with the fraction anticipated to decrease
per day with continued use.
Body weight distributions were assumed to be the same for all
exposure routes and detailed description of bodyweight data relied
upon has been provided previously in section 2.3.1. Inhalation rates
used in the Monte Carlo Analysis were obtained from USEPA (2011)
and are provided in Supplementary Table S-10.
The bioavailability fraction for D5 in foodwas determined from a
study reported in Jovanovic et al. (2003) to evaluate the absorption
of [14C]-D5 by various carriers after a single oral dose (i.e., corn oil,
simethicone ﬂuid, and neat [14C]-D5). Doses of D5 in each carrier
were administered to female Fischer 344 rats. The mass balance
data obtained showed that 19.62%, 25.81%, and 9.94% of the
administered [14C]-D5 was absorbed when delivered in the corn oil,
simethicone ﬂuid, and neat [14C]-D5, respectively. These percent-
ages were used as the bioavailability fractions for all food products.
A normal distribution with a mean of 19.62% and a standard devi-
ation of 0.042 was used. For OTC medications and antifoam in food,
the absorption reported for D5 in simethicone ﬂuid was used as a
normal distribution with mean of 25.81% and a standard deviation
of 0.044.
2.3.1.3.1. General public. The various consumption rates of
environmental media/food for the General Public receptor for wa-
ter, soil, ﬁsh, milk, meat and vegetables was based on information
from USEPA (2011), Health Canada (2008), CSFII 1994e96 (USDA,
1998) and Kitakanto Branch of the Environmental Control Center
Co. of Japan (Environmental Control Center Co. 2011). Concentra-
tions of D5 in the various media ranging from 8.30  106 to 1 mg
D5/kg of food were based upon data, either measured or predicted,
provided in Brooke et al. (2009), Health Canada (2008), Boehmer
and Gerhards (2003), Norden (2005), NILU (2007), and Kitakanto
Branch of the Environmental Control Center Co. of Japan
(Environmental Control Center Co. 2011). This included concen-
trations of D5 for water, ﬁsh, meat, milk, and vegetables. Concen-
trations of D5 in breast milk were obtained from Kaj et al. (2005).
Concentrations of D5 from antifoam in food were provided in
two Dow Corning Corporation internal reports (Dow Corning
Corporation, 2004, 2007) and varied from 0 to 10 ppm. The per-
centage of antifoam in food is consistent with the USFDA code of
regulations (USFDA, 2012) for the maximum concentration of
defoaming agents in processed foods of 10 ppm and the EU
(European Commission, 2011) database on Food Additives
(European Commission, 2011). It was assumed that 50% of the food
consumed would contain antifoam which is a very conservative
estimate as antifoam is only contained in some processed food
(excluding milk andmilk products). A triangular distributionwith a
most likely value of 5 ppm and a maximum value of 10 ppm was
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foam. For the child receptor, a subsistence ﬁsh consumption rate
and consumption rates for breast milk were obtained from USEPA
(2006b).
2.3.2. Application of PBPK model
The ﬁnal step of the exposure assessment was conducted using
the PBPK model (McMullin et al., 2015). This model was executed
with human parameter values (for both physiological parameters,
such as ventilation rate or cardiac output, and for D5-speciﬁc pa-
rameters, such as partition coefﬁcients) to develop estimated in-
ternal dose-metrics that were unique to the receptor, route of
exposure, and exposure pattern.
Characterization of exposure scenarios and estimation of D5
intake for the selected receptors (i.e., worker, consumer, general
public) were conducted. These parameter values were used with
the PBPK model to determine the AUC, the internal dose metric in
arterial blood that was receptor- and exposure scenario-speciﬁc.
The values for the parameters used within the PBPK model were
the most-likely values from the triangular distribution, the mid-
point of the uniform distribution, or the mean value for a
lognormal or normal distribution as described in the Monte Carlo
analysis.
For the analysis of oral intake for the PBPK model, the output
from the second Monte Carlo analysis was used to estimate the
amount of intake of D5 from the combined oral sources of food,
water, soil, antifoam and lipstick. The individual consumption of D5
taken in with root crops, greens, meat, milk, water, antifoam, soil,
and ﬁsh were summed for males and females with the addition of
D5 in lipstick for females. For the subsistence ﬁsherman, the dis-
tribution of amount of ﬁsh consumed was obtained from USEPA
(2006a). One hundred thousand iterations were run in the Monte
Carlo analysis which provided distributions of daily intakes. The
mean and 90th percentiles of the distributions for teens and adults
both for the general public and for subsistence ﬁshermenwere used
for input in the PBPK model as estimates of the daily intake of D5
from the oral route.
2.3.2.1. Occupational. As stated earlier no analysis of potential oral
exposure to D5 for a worker was conducted in the Monte Carlo
analysis and no exposure to D5 through the oral (ingestion) sce-
nario was expected to occur during occupational exposure; there-
fore, exposure to workers was limited to the dermal and inhalation
scenarios only. Barbers and Beauticians were the only occupation
workers considered to have the potential for dermal exposure
through the application of HC products containing D5.
Data on application rates, the fraction of product deposited on
the skin, the fraction of residue left by rinse-off products on skin,
and the amount of D5 in hair care products were collected to
determine the product that would provide an upper bound esti-
mate of the amount of D5 to which the workers could be exposed.
Based on information provided in Table 1, the use of conditioner
products would provide the largest amount of exposure to D5 to a
barber/beautician. This was determined by multiplying the grams
of application by the percentage of D5 in the product and the
deposition and residue fraction. Therefore, to get the most con-
servative estimate of exposure and therefore the highest internal
dose metric using the PBPK model, the data for conditioner prod-
ucts were used because it was the HC product that would result in
the highest exposure to D5, when the application rate, the per-
centage of D5 in the product, and the deposition and residue frac-
tions were considered. This information is considered a
conservative representative exposure for HC products because the
amount of D5 in conditioners is four times higher than any other
product considered and approximately 60 times higher thanshampoo (the most used HC product). Other PBPK input parame-
ters used are provided in detail in Table 2.
D5 air concentrations were measured in the workplace using
personal monitors for the following groups of workers that may be
exposed to D5 via inhalation during the performance of their job: 1)
workers involved in the formulation of AP/Ds; 2) workers involved
in the manufacture of HC/SC products; 3) workers in dry cleaning
establishments that use GreenEarth solvent; 4) workers in a D5
production facility; and, 5) barbers and beauticians. For workers
involved in the production of D5, an arithmetic mean, time-
weighted average D5 air concentration of 0.0587 ppm was esti-
mated (Maxim, 1998). For workers in plants that formulated con-
sumer products containing D5, Maxim (1998) reported average
concentrations of 2.23 ppm for AP workers, 1.06 ppm for SC
workers, and 0.002 ppm for HC workers (Table 3). Representative
air concentration of 0.143 ppm and 0.008 ppm were obtained for
dry cleaners (Severn Trent Laboratories, 2001) and beauticians and
barbers (Maxim, 1998), respectively (Table 3). Several indoor air
data concentrations were also evaluated to represent the range of
exposures to a general ofﬁce worker. The value of 9.7 mg/m3
(Norden, 2005) (Table 10) was used within this assessment to
represent the mean exposure to a resident which could be repre-
sentative of someoneworking out of their home. The value of 39 mg/
m3 (Shields et al., 1996) was used to represent the mean exposure
to an ofﬁce worker (Table 10). A concentration of 120 mg/m3 (Wu
et al., 2011) was used as the upper bound on indoor air exposure
as this was larger than most of the ranges given. An inhalation rate
for moderate activity of 1.6 and 1.4 m3/hour for males and females,
respectively, were used for workers during the work day (USEPA,
2011) (Table 3).
The U.S. Department of Labor's Bureau of Labor Statistics (2012)
reported the range of hours in the annual average work week for
barber shops and beauty salons to be from 26.3 hours to 28.3 hours
for the years 1995 through 2012. An average of 28 hours per week
or 5.6 hours per day for 50 weeks out of the year was used for both
the dermal and inhalation analysis.
For most workers exposed to D5 (e.g., workers in antiperspirant,
skin care and hair care plants and dry cleaner workers), a standard
8 hour work day was assumed. However, due to the manner in
which shifts were typically scheduled for silicone workers, an
8.75 hour day was used (Maxim, 1998) and is consistent with other
recently published data (US Bureau of Labor Statistics, (2013)).
For all occupational exposures analyses, tenure was used to
deﬁne the number of years over which exposure might occur. Ac-
cording to Carey (1988), as cited in the USEPA Exposure Factors
Handbook (2011), occupational tenure was deﬁned as the “cumu-
lative number of years a person works in his or her current occu-
pation, regardless of the number of employers, interruptions in
employment, or time spent in other occupations.” The weighted
average of the median tenure, in years for full-time workers be-
tween the ages of 16 and 59 was 10.2 years for men and 6.4 years
for women (USEPA, 2011). Considering a lifetime to be 75 years for
men and 80 years for women (USEPA, 2011), the occupational ex-
posures were adjusted by 10.2/75 for men and 6.4/80 for women.
For the dermal exposure scenario for barbers and beauticians,
the frequency of a hair product being applied was assumed to occur
once every 30 min during the work day for a 5 day work week and
every 27 min for a 4 day work week. Therefore, the number of
applications of HC products in a day was assumed to be 12 to 15
over a 5 or 4-dayworkweek for 50weeks per year. The HC products
used by barbers and beauticians were assumed to contact both
sides of the hands which represent a surface area of 890 cm2 in
females and 1070 cm2 in males.
Alveolar ventilation rates used for the inhalation exposure
analysis were equivalent to pulmonary ventilation rates of 1.6 and
Table 1
Hair care products used by barbers/beauticians containing D5.
Hair care products Application rate (g/use) Midpoint D5 (%) Amount of exposure to D5 (g/use)
Shampoo 6e 0.02f 0.0012
Rinse-out Conditioner 13.77b 44.5f 6.1277
Leave-in Conditioner 13.77b 44.5f 6.1277
Hair Spray 5.8d 27c 1.3986
Brilliantine 4.7a 2.8a 0.1316
Pomade 4.7a 1.9a 0.0893
Spray Shine 5.6a 5a 0.28
a Maxim 1998.
b Mean value form Loretz et al., 2008.
c Maximum midpoint of ranges presented in studies (see Tables 4 and 5).
d Mean value form Loretz et al., 2006.
e Mean value from Hall et al., 2007.
f Midpoint from range in Johnson et al., 2011.
Table 2
Summary of dermal exposure parameters e barbers and beauticians.
Parameter Barbers and beauticians Sources
Men Women
Amount Hair Product applied (g) 13.77 13.77 Loretz et al., 2008
Amount of D5 (%) 56 56 Johnson et al. (2011); Median value from D5 in other noncoloring hair products
Residue Fraction 0.01 0.01 See Section 2.3.1.1
Exposure Frequency (applications per day) 12 12 Professional Judgment
Days per week 5 5
Weeks per year 50 50
Surface Areaa (cm2) 1070 890 USEPA 2011
Body Weight (kg) 87 73 CDC (2007e2010)
a Surface area of the hands.
Table 3
Summary of inhalation exposure parameters e workers.
Worker Air concentrationa
(ppm)
Daily exposuree (hours/
day)
Parameter exposure frequencye (days/
week)
Work yeare (weeks/
year)
Inhalation ratef (m3/
hr)
Body weightg
(kg)
Antiperspirant 2.23 8 5 50 1.6 (M) 86.9 (M)
(1.07) 1.4 (F) 73.4 (W)
Skin Care 1.06 8 5 50 1.6 (M) 86.9 (M)
(0.83) 1.4 (F) 73.4 (W)
Hair Care 0.002 8 5 50 1.6 (M) 86.9 (M)
(0.001) 1.4 (F) 73.4 (W)
Dry Cleaner 0.143 8 5 50 1.6 (M) 86.9 (M)
(0.103) 1.4 (F) 73.4 (W)
Silicone 0.0587 8.75c 5 50 1.6 (M) 86.9 (M)
(0.0286)b 1.4 (F) 73.4 (W)
Barbers and
Beauticians
0.008h 5.6d 5 50 1.6 (M) 86.9 (M)
1.4 (F) 73.4 (W)
a Values are reported as arithmetic mean (geometric mean). The arithmetic mean was used in the assessment. Results from Maxim (1998) unless otherwise speciﬁed.
b Arithmetic and geometric mean concentrations from all types of silicone workers.
c Based upon results for silicone workers are reported in Maxim (1998).
d Based upon The US Bureau of Labor Statistics (2012).
e Defaults based upon professional judgment.
f Inhalation rates as reported in USEPA (2011).
g Body Weights based upon NHANES (2007e2010) data.
h Value based on sample from Wu et al. (2011). Similar value of 0.006 ppm presented in Maxim (1998).
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and 0.8 and 0.7 m3/hour for non-work hours for males and females.
Cardiac output rates were calculated based on an equation relating
alveolar ventilation and cardiac output (Clewell et al., 2004). The
evaporation rate of D5 from the site of application and the ab-
sorption rate into the skin were adjusted based on the available
data (Reddy et al., 2007).
2.3.2.2. Consumers. The key considerations in estimating internal
dose metrics associated with dermal exposure from the use of
consumer products were the amount of D5 in the product, theamount applied, the surface area over which the product was
applied, and the frequency of that application. The values for these
parameters are presented in Tables 4 and 5. The surface area to
which a consumer product is applied differs based upon the
product and the receptor to which the product is being applied. For
many of the products that contain D5, the surface area is estimated
based upon a percentage of the body part to which the product is
applied. The surface areas used to derive the application areas used
in the PBPK analysis are summarized in the Supplementary Table S-
8. Median axilla surface areas were reported for females and males
in Cowan-Elsberry et al. (2008) (64.5 cm2 and 135.5 cm2,
Table 4
Application parameter values for consumer user.
Product Application rate (gms/day) Application frequency (application/day)h Midpoint D5 (%)b
Antiperspirant/Deodorant gel or roll-on 1.22 (male)c 0.898 (female)c 1.3 40.5
Antiperspirant/Deodorant stick or solid 0.79 (male)f 0.61 (female)f 1.3 40.5
Antiperspirant/Deodorant aerosol 3.478c 1.3 40.5
Shampoo 6c 1 0.02
Conditioner (Leave-in) 13.77e 1 44.5
Conditioner (Rinse-out) 13.77e 1 44.5
Hair Care e Hair Spray
Aerosol 3.57f 1 18.1
Pump 5.18f 1 18.1
Cosmetic Foundation 0.33g 1 50
Cosmetic Under-eye Cream 0.06a 1 11.2
Cosmetic Mascara 0.11a 1 16.8
Cosmetic Lipstick 0.025c 1 28.5
Skin Care e After Shave Gel 0.95a 1 11.5
Skin Care e Lotion (Hand/Body) 8.69c 1 44.2
Skin Care e Moisturizer 0.91c 1 47
Skin Care e Nail Care 0.25a 1 47
Skin Care e Sunscreen 6.1a 1 24.6
Soothing Vapor 5d 2 0.03
a For Maxim (1998), maximum application rates were selected as those having greater than a 1% response for those numbers of days.
b Midpoints calculated from Johnson et al. (2011).
c Hall et al. 2007.
d Meeks 2005.
e Loretz et al. 2008.
f Loretz et al. 2006.
g Hall et al. 2011.
h Personal judgment.
Table 5
Surface for dermal evaluation of consumer exposure to antiperspirant/deodorant, hair care, and skin care products.
Product type Surface area (cm2) Area description Basis
Male Female
Antiperspirant/Deodorant e gel/roll-on, stick/solid, and aerosol 271 129 Both axillae Cowan-Ellsberry et al. 2008
Hair Care e hair spray (aerosol and pump) 680 570 ½ head USEPA 2011
Cosmetic e foundation Skin Care e Moisturizer NA 570 ½ head USEPA 2011
Cosmetic e under-eye cream NA 11.4 1% of head USEPA 2011
Skin Care e after shave gel 340,535 NA ¼ head ½ hands USEPA 2011
Skin Care e lotion (hand/body), sunscreen 20,670 17,000 Body e Head USEPA 2011
Skin Care e nail care NA 11 SCCS 2003
Table 6
Summary of inhalation exposure parameters for consumer product exposure.
Parameter Men Women Source
Air Concentration (AC)
AP/C Solid 0.2 ppm 0.2 ppm Andersen and Weaver 1989
AP/D Roll-on 1.7 ppm 1.7 ppm
AP/D Aerosol 0.65 ppm 0.65 ppm Maxim 1998
HC/SC Products 0.178 ppm 0.178 ppm
Exposure Duration (ED) 5 min 10 min USEPA 2011 a
Application Factor (AF)
AP/D Products 9.1 apps/week 9.1 apps/week Loretz et al. 2006
HC/SC Products 7 apps/week 7 apps/week Professional judgment
Inhalation Rate (INH) 0.8 m3/hour 0.7 m3/hour USEPA 2011
Body Weight (BW) 86.9 kg 73.4 kg CDC (2007e2010)
a Median time spent in bathroom.
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values reported in Cowan-Ellsberry to take in consideration of
application of antiperspirants/deodorants to both axilla.
Exposures to various products containing various amounts of D5
were assumed to occur once per day for various numbers of days
per week for both men and women (Table 4). Consumer products
for which there were exceptions to this exposure scenario included
moisturizer exposure, which was simulated to occur twice per day
(once every 12 hours), and sunscreen exposures, which wereassumed to occur for eleven consecutive days once per year.
For the consumer inhalation analysis, no speciﬁc information on
resulting air concentrations in areas following use of consumer
products was available for all of the products containing D5.
Therefore, the PBPK modeling was conducted using air concentra-
tion data that was available for selected consumer products.
The average case breathing zone concentrations of D5 were
estimated to be 0.2, 1.7, and 0.65 ppm for solid, roll-on, and aerosol,
respectively. These values were based on data obtained from a
Table 7
Summary of inhalation exposure parameters for general public.
Parameter Value Source
Air Concentration
Indoor 34.5 mg/m3 (0.00227 ppm)
or
393 mg/m3 (0.0259 ppm)
Health Canada 2008;
NYIEQ 2005
Outdoor 0.5 mg/m3 (0.00003 ppm) Shields et al. 1996
Exposure Duration
Indoor 24 h/day Professional judgment
Outdoor 24 h/day Professional judgment
Exposure Frequency 7 days/week Professional judgment
Year 52 weeks/year Professional judgment
Inhalation Rates (m3/hour) 0.8 (male)
0.7 (female)
USEPA 2011
Body Weights (kg) 86.9 (male)
73.4 (female)
CDC (2007e2010)
a since the PBPK model is not set up for accounting for varying inhalation exposure during the day, 24 h exposure to either indoor and
outdoor air was assumed.
Table 8
Dose-response model predicted BMDL10.
Incidence of uterine endometrial
adenomas
Exposure dose
(ppm)
Adjusted exposure doses (ppm) adjusted to continuous from 6 h per day and 5 days
per week
Human equivalent doses
(HED)
AUC (mg-hrs/L/day)
0/60 0 0 0
1/60 10 1.79 0.35
0/60 40 7.14 1.39
5/60 160 28.57 5.57
BMDL10 131 23.43 4.57
Table 9
Results of BMDS Modeling for the incidence of Uterine Adenocarcinomas in Female Rats.
Model Name AIC P-value Scaled residual of interest BMDa (ppm) BMDL (ppm) BMDb (ppm) BMDL (ppm) BMDc (mg-hrs/L/day) BMDL (mg-hrs/L/day)
Gamma 52.801 0.156 0 166.2 135.5 29.67 24.19 5.79 4.72
Logistic 51.173 0.301 0.043 173.7 141.0 31.02 25.18 6.05 4.91
LogLogistic 52.801 0.156 0 163.6 135.1 29.21 24.11 5.70 4.71
LogProbit 52.801 0.156 0 167.1 132.5 29.82 23.65 5.82 4.61
Multistage 50.947 0.354 0.035 175.3 131.3 31.31 23.43 6.11 4.57
Multistage-Cancer 50.947 0.354 0.035 175.3 131.3 31.31 23.43 6.11 4.57
Probit 51.251 0.295 0.063 177.4 137.3 31.68 24.52 6.18 4.78
Weibull 52.801 0.156 0 163.5 134.8 29.19 24.05 5.70 4.69
Quantal-Linear 52.010 0.275 0.291 224.0 117.4 39.98 20.95 7.80 4.09
a The doseeresponse models were ﬁt to the data using the animal exposure doses unadjusted.
b The doseeresponsemodels were ﬁt to the data using the animal exposure doses adjusted from 6 h per day, and 5 days per week to continuous (i.e. multiplying by 6/24 and
5/7).
c The doseeresponse models were ﬁt to the data using the internal dose-metrics for average daily area under the curve (AUC) of the concentration of free D5 in arterial
blood.
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which three different commercial D5-containing AP/Ds (solid, roll-
on and aerosol) were applied by two male participants in a 30 m3
room using a typical application amount and a relatively heavy
application. These values were calculated as the average of the high
application and lower application time-weighted average concen-
tration of cyclics measured multiplied by the percent D5 in that
product.
A time-weighted average D5 concentration of 0.178 ppm was
determined for general HC products. This value was based on a
study in which six personal monitoring samples were taken while
six volunteers were using shampoos, conditioners, and hair sprays
containing D5. Following application of the HC products, users
remained in the room where the products were applied for
17e40 min. Since no studies were identiﬁed related to SC products,
0.178 ppm was also assumed as representative of these productsand was assumed applicable to both men and women.
There were no consumer use data for the amount of time that
elapses between the application of an AP/D, HC, or SC product and
subsequent dressing, e.g., putting on a shirt or top, during which
time a consumer would be exposed to D5 vapor during this time D5
air concentrations would be expected to be highest, particularly if
bathing, application, and dressing occurred in a closed bathroom.
For this assessment, the time spent in the bathroom following a
bath or shower was used as an estimate of the length of time that a
consumer would be exposed to D5 in the air. Using the median
percentile from the time spent in the bathroom after a bath or
shower reported from the Exposure Factors Handbook (USEPA,
2011) gives a weekly time of 0.58 hours/week for men and
1.17 hours/week for women.
The frequency of use for AP/D for this exposure assessment was
set at 1.3 applications per day or 9.1 times a week (Loretz et al.,
Table 10
Area under the curve: Occupational Exposure.
Worker AUC (mg-hrs/L/day)
Men Women
Dermal Exposure
Barbers and Beauticians
5 days 3.6  104 3.6  104
4 days 3.7  104 3.7  104
Inhalation Exposure
Antiperspirant 9.6  102 9.4  102
Skin Care 4.6  102 4.5  102
Hair Care 8.6  105 8.5  105
Dry Cleaner 6.1  103 6.0  103
Silicone 2.8  103 2.7  103
Barbers and Beauticians 2.4  104 2.4  104
Ofﬁce Worker
9.7 mg/m3 2.6  105 2.5  105
39 mg/m3 1.0  104 1.0  104
120 mg/m3 3.2  104 3.1  104
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in ten different geographical locations in the US who were asked to
keep a diary of use of a solid antiperspirant for two weeks (Loretz
et al., 2006). No reported information was available in the study
for aerosols and roll-on antiperspirants, and their application fre-
quency was assumed to be similar. Additionally, this value is ex-
pected to be suitable for a man's use of antiperspirant. This value
differs from the application frequency used in the dermal contact
evaluation since that evaluation had an application rate based on a
gram per day basis indicating an implied application frequency of
once per day.
Soothing vapor was identiﬁed as a consumer product of interest
based upon the potential volatilization of D5 into air. The air con-
centration for soothing vapor was estimated by multiplying the
percent of D5 in soothing vapor (0.03%) by the grams applied (5 g
per day) multiplied by two applications per day. This result was
then divided by an estimated room volume of 10 m3 resulting in a
D5 air concentration of 0.3 mg/m3 (or 0.02 ppm). This was assumed
to be a consistent dose in the room in which the person applying
the soothing vapor stayed.
The PBPK simulations for the inhalation exposure of consumers
used the same alveolar ventilation rates and cardiac outputs as the
dermal simulations with the frequency of application and other
parameters as described above. As with the dermal simulations, the
AUC was determined following one year of exposure.2.3.2.3. General public. NYIEQ (2005) identiﬁed a value of 34.5 mg/
m3 as representative of the indoor air concentration to which an
individual would be exposed. As a conservative bounding estimate
a value of 393 mg/m3 representing the 90th percentile from all
available data was estimated by Health Canada (2008) and was also
used to predict the amount of exposure from indoor air. A value of
0.5 mg/m3 was identiﬁed (Health Canada, 2008) as representative of
the typical exposure to D5 in outdoor air to estimate D5 exposure for
the general public. Although the general public would be assumed
to be exposed to a combination of concentrations of D5 in indoor air
for a certain number of hours and to outdoor air for the remainder
of the day simulating this was not possible with the current PBPK
model. For this evaluation, estimates of exposure for the general
public were estimated under the assumption that a person would
be indoors 24 hours per day or outdoors 24 hours per day. This
bounds the potential for exposure with outdoor exposure repre-
senting the minimum and indoor exposure representing the
maximum, while the exposure from being present both indoors
and outdoors during the day falls somewhere between. Otherrequired parameters used in the PBPK model are identiﬁed in
Table 7.
The PBPK simulations were run to simulate 1 year of exposure
and were assumed to be representative of any given year. The same
alveolar ventilation rates and cardiac outputs were used for these
simulations as were used for the consumer simulations.
The PBPK simulations for the oral exposure of the general public
and subsistence ﬁsherman used amodiﬁed version of the oral PBPK
model. The existing version of the model (McMullin et al., 2015)
only allows for a single bolus dose or intake to be applied per day.
As the oral intake of D5 from either food or lipstick products is
anticipated to be episodic based on the standard of multiple meals
per day for food intake and multiple applications of lipstick per day
(Loretz et al., 2005), the PBPK model was modiﬁed to allow for
episodic rather than bolus or continuous intake. The estimated
mean and the 90th percentile of total daily oral intake of D5 for
adults was estimated using a Monte Carlo analysis. This intake was
a combination resulting from the consumption of D5 in root crops,
greens, meat, milk, water, antifoam, soil, lipstick and seafood
determined by the MC analysis. The intake was divided into ﬁfths,
allowing for episodic equal intakes of one-ﬁfth of the total daily
consumption of D5, spaced out over the day at 8 AM, 10 AM, 12 AM,
4 PM and 7 PM.
2.4. Risk characterization
In this assessment, rather than attempting to derive uncertainty
factors that may be used by the various regulatory agencies and
programs (i.e. Health Canada, REACH, SCCS, OSHA, USEPA) to adjust
the POD for low-dose extrapolation, a comparison of the internal
dose metric associated with the POD to the internal dose metric
estimated for each exposure scenario was conducted. The use of
these ratios or Margins of Safety (MOS) removes the need to
consider various uncertainty factors that may be applied across
various regulatory agencies globally.
In evaluating each MOS for different exposure scenarios,
different MOSmay be protective of human health. For occupational
exposures, OSHA considers a risk of 1  104 or less as acceptable.
In applying uncertainty factors to the POD, OSHA may include a
factor of 10 for intrahuman variability and a factor of 3 for
extrapolation from animal-to-human allowing for uncertainties in
pharmacodynamics across species. In comparison, the highest un-
certainty factor applied in the REACH Chemical Safety Report
(REACH, 2011) in the derivation of occupation DNELs for D5 was 3
for intraspecies differences. Based on the highest anticipated factor
of 30 for noncarcinogenic effects, a MOS of greater than 30 would
be acceptable.
For environmental exposures or exposures through the use of
consumer products, the highest uncertainty factor applied by
REACH in the D5 assessment was 10. For USEPA in the derivation of
RfC or RfD values, the factors typically applied to the POD would
include factors of up to 10 andwould account for one ormore of the
following uncertainties: intrahuman variability, interspecies
extrapolation, use of precursor data, and remaining sources of
uncertainty in the database. This would include a factor of 10 for
intrahuman variability, 3 for extrapolation from animal-to-human
allowing for uncertainties in pharmacodynamics across species
(although it could be argued that a factor of 1 is appropriate
because it is expected that womenwould be less sensitive than the
rodent to modiﬁcations in hormone balance), 10 for the use of tu-
mor rather than precursor data, and 3 for remaining sources of
uncertainty related to the database. This last factor may be applied
due to lack of a chronic inhalation toxicity/carcinogenicity study in
multiple species. Therefore, based on the uncertainty factors that
could be applied by regulatory agencies or authoritative bodies
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indicate no signiﬁcant risk of adverse effects due to the exposure
scenarios being considered.
3. Results
3.1. Hazard identiﬁcation
The available toxicological data for D5 (Dekant and Klaunig this
issue) and regulatory reviews of these data (Environmental Control
Center Co. 2011; Health Canada, 2008; Lassen et al., 2005; REACH,
2011; REACH Registration Dossier, 2011; SCCS, 2010) have identi-
ﬁed the liver as a potential target organ following repeated-dose
oral exposure and liver, lungs and uterus as potential target or-
gans following repeated-dose inhalation exposure. No signiﬁcant
toxicological effects were observed following repeated-dose
dermal exposure to D5 following exposure to doses as high as
1600mg/kg bw/day. Based on the literature D5 is not genotoxic. The
only treatment-related endpoint identiﬁed following inhalation
exposure to D5 was the statistically signiﬁcant increase in uterine
adenocarcinomas observed in female rats following 24 month
exposure to 160 ppm D5. The incidence of these tumors was 0/60 in
the control and 1/60, 0/60 and 5/60 in the low, mid- and high
treatment groups, respectively. Survival was not affected in any
treatment group, with the ﬁrst uterine adenocarcinoma found in an
animal in the low dose group after approximately 1.5 years of
exposure, while those noted in the high exposure groupwere found
at or near terminal sacriﬁce. The tumors in the treated groups were
also histologically indistinguishable from those found in control
rats in other NTP studies (Experimental Pathology Laboratories,
2003).
Following both oral and inhalation exposure (14 dayse3
months) to D5, increases in liver weights were reported. Because no
accompanying histopathological changes were observed in these
studies and no liver effects were reported in the chronic inhalation
toxicity/carcinogenicity study, these effects have been suggested to
be adaptive, non-adverse transient effects in the rodent. Further,
enzyme induction studies conducted in rats indicate induction of
Cytochrome P450 pathways that are consistent with the classical
response observed following phenobarbital treatment. This in-
dicates that D5 was a weak phenobarbital-type inducer in the rat
liver. However, it has also been noted that there may be important
mechanistic differences between rodents and humans in
phenobarbital-type inducers (Health Canada, 2008; Zhang et al.,
2000). While these changes have been assessed as relevant to hu-
man health, it is also unclear as to whether they would represent
“adverse” changes, due to the lack of accompanying histological
changes in the rodent and the lack of liver effects at the terminal
sacriﬁce in the chronic inhalation toxicity/carcinogenicity study. In
summary, D5 is a not a genotoxic carcinogen and while the results
of mode of action studies are not clear, the tumorogenic effects
observed in Fischer 344 female rats may be species-speciﬁc with no
risk or relevance to human health.
3.2. Dose-response assessment
3.2.1. Selection of data and approach for dose-response modeling
Based on the review of the toxicological literature on D5, dos-
eeresponse modeling was conducted relying upon the incidence of
uterine adenocarcinomas in female rats after inhalation exposure
to 160 ppm of D5 for two years (Experimental Pathology
Laboratories, 2003). Administration of D5 did not produce other
signiﬁcant, treatment-related carcinogenic or noncarcinogenic ef-
fects in the chronic inhalation toxicity/carcinogenicity study, nor
were any clearly relevant, treatment-related adverse effects notedin reproductive or immunotoxicity studies.
The incidence of uterine adenocarcinomas (0/60, 1/60, 0/60 and
5/60 in the control, low, mid- and high treatment groups, respec-
tively) does not increase with increasing exposure concentration,
with no statistically signiﬁcant increase in tumor incidence only
observed at the highest concentration tested (160 ppm). While the
mode of action of D5 in the production of uterine tumors is un-
known, there is some evidence that the tumors are occurring by a
nonlinear mode of action. Based on the literature D5 is not geno-
toxic. Carcinogens acting by a linear mode of action are generally
considered to be DNA reactive and have direct genotoxic activity. In
general, a nongenotoxic carcinogen that exhibits a threshold
response has a POD that is either the externally derived no
observed adverse effect level (NOAEL) or the benchmark dose
(BMD). Uncertainty or safety factors are then applied to the POD to
develop permissible exposure levels at which no relevant human
cancer risk are anticipated. However, there are limitations to the
NOAEL approach, which have been used in prior risk assessments
conducted for D5 (Health Canada, 2008; REACH, 2011; SCCS, 2010).
These limitations to the NOAEL approach have been summa-
rized in the 1995 USEPA Benchmark Dose Approach guidance
(USEPA, 1995) and include: 1) Whether or not a given experimental
dose actually constitutes a NOAEL is subject to scientiﬁc judgment
and is often a source of controversy; 2) Larger NOAELs can result
from experiments involving fewer animals, that is, a poorly
designed study may be “rewarded”; 3) The shape and slope of the
dose response is not considered in the determination of the NOAEL;
4) The NOAEL (if one exists) must be one of the experimental doses;
and 5) Use of a NOAEL does not provide estimates of potential risk
at any exposure level. As an alternative, the BMD approach (i.e., the
maximum likelihood estimate of the dose associated with a spec-
iﬁed increase in risk or change in response) has been proposed for
determining a POD for development of a toxicity value that can be
used in setting exposure limits and has several advantages over the
NOAEL approach. These advantages include: 1) The BMD approach,
unlike the NOAEL, takes into account the doseeresponse informa-
tion (i.e., the shape of the doseeresponse curve); 2) The BMD
approach does not involve sometimes argumentative “all or
nothing” decisions, such as determining whether or not a NOAEL
was deﬁned at a particular dose; 3) The BMDL, a lower conﬁdence
limit, appropriately reﬂects the sample size of a study (smaller
studies tend to result in wider conﬁdence limits and lower PODs,
whereas the opposite is true for NOAELs); and 4) A POD from the
BMD approach can be determined evenwhen a NOAEL has not been
identiﬁed in a study. Therefore, taking into account the limitations
of the NOAEL/C/LOAEL/C approach for determining the POD, the
BMD approach was chosen as the method for derivation of a POD
for D5 in this assessment.
3.2.2. Estimation of the human equivalent dose
Simulations were run with the rodent PBPK model using the
female rat parameters to simulate exposure for 6 h per day, 5 days
per week, for 2 years to 10, 40 or 160 ppm D5 to derive the AUC of
the free D5 in the blood in the rat for each experimental concen-
tration applied in the Experimental Pathology Laboratories (2003)
study (Table 8). It was assumed that the resulting AUC in the rat
is the AUC for estimating the human equivalent concentration
(HEC), which is consistent with the application of other PBPK
models (Clewell and Andersen, 1985; Clewell and Clewell, 2008;
Clewell et al., 2001a, 2001b; Gentry et al., 2011; Reddy et al.,
2008). The human PBPK model was then used to provide the hu-
man AUCs for each of the exposure scenarios considered (Section
4.0) for comparison to the estimated POD from the doseeresponse
modeling. Since the POD is in terms of the rat AUC, and the rat AUC
is assumed to be equivalent to the human AUC or the relevant
Table 11
Area under the curve (AUC) (mg-hrs/L-day): Selected consumer products.
Product Dermal Inhalationa
Men Women Men Women
Solid Deodorant 6.0  104 4.1  104 1.2  104 2.4  104
Roll-on Deodorant 1.2  103 6.0  104 1.0  103 2.0  103
Aerosol Deodorant 5.3  104 1.8  103 4.0  104 7.7  104
Shampoo 1.5  108 3.3  1010
Conditioner (Rinse-out) 7.7  105 7.8  105
Conditioner (Leave-in) 3.8  104 3.9  104
Hair Spray (aerosol) 2.3  105 2.3  105 1.1  104 2.1  104
Hair Spray (pump) 3.3  105 3.4  105 1.1  104 2.1  104
Moisturizer 1.1  103 1.1  103 1.1  104 2.1  104
Foundation N/A 1.4  104 N/A 2.1  104
Under eye cover N/A 7.3  106
Lipstick (6 days) N/A 2.3  105
Lipstick (5 days) N/A 1.9  105
Mascara N/A 4.2  105
Hand/Body Lotion 5.0  103 5.2  103 1.1  104 2.1  104
Sunscreen 7.0  105 6.5  105 1.1  104 2.1  104
Nail Care N/A 3.6  107 N/A 2.1  104
After Shave Gel 9.8  105 N/A 1.1  104 N/A
Soothing Vapor N/A N/A 3.5  105 3.5  105
a Non-deodorant inhalation exposure were based upon results reported in a
single study.
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concern, the human AUCs for each exposure scenario can be used to
determine MOS using the ratio of these values.
3.2.3. Estimation of point of departure
The BMDs and BMDLs derived using the BMDS software are
presented in Table 9 including the goodness-of-ﬁt criteria. The
model chosen as the “best ﬁt” to the incidence of uterine adeno-
carcinomas was the Multistage model, which has the form:
pðdÞ ¼ gþ ð1 gÞ 

1 eq1dþq2d2…qkdk

where P(d) is the probability of developing cancer from a lifetime
continuous exposure at that dose, qi ¼ 1, … k are the ﬁtted dose
coefﬁcients of the model, and k is the number of stages selected
through the best ﬁt of the model, typically not greater than one less
than the number of dose groups. Using the continuous animal
exposure doses in the evaluation of the tumor data, the estimate of
the exposure in ppm at a BMR of 10%, the BMDL10 or POD is
23.43 ppm. Using the internal dose-metrics (AUC of free D5 in the
blood), the BMDL10 is 4.57 mg-hrs/L/day.
3.3. Exposure assessment
3.3.1. Estimates of exposure based on Monte Carlo Analysis
The results of the Monte Carlo analysis were used to prioritize
the potential pathways for adults in which internal dose metrics
would be estimated for the development of MOS. The results from
the Monte Carlo analysis provided information as to exposure to
which consumer products would result in the highest potential for
D5 exposure (e.g., food, consumer products, etc.). It was determined
from the Monte Carlo analysis that in adults in all cases, consumer
product use provided the highest contribution to potential D5
exposure, with use of body lotion, hair spray, foundation, after
shave and APs providing the highest estimated intakes in adults.
Estimates of intake determined by the Monte Carlo analyses for
remaining pathways for both adults were 55% than the estimated
intake of D5 from use of body lotion in females. These results
demonstrate that it is not likely that these pathways would
represent a signiﬁcant contribution to the potential exposure to D5
that could occur via multiple pathways.
Results of common exposure scenarios from the Monte Carlo
analysis in children resulted in similar estimates of intake as the
adults. For example, in general, diaper cream was the driving
exposure scenario for children under 4 years of age and body lotion
for children 4e11 years old. Comparison of the values indicated that
child exposurewas nomore than 2 times higher than that of adults.
Comparisons of other exposure scenarios between adults and
children produced results where the intakes were close to the same
or the child slightly greater than the adult. The current PBPK model
(PBPK model, in press) is not designed to estimate internal dose
metrics for children. Therefore, these scenarios were not evaluated
in the PBPK analysis, but were qualitatively related to the PBPK
results from scenarios evaluated in the PBPK analysis. The
Supplementary Tables S-11 through 13b provide results from the
Monte Carlo analysis.
3.3.2. Application of PBPK model
3.3.2.1. Occupational. As stated earlier no analysis of potential oral
exposure to D5 for a worker was conducted in the Monte Carlo
analysis and no exposure to D5 through the oral (ingestion) sce-
nario was expected to occur during occupational exposure; there-
fore, exposure to workers was limited to the dermal and inhalation
scenarios only. Barbers and Beauticians were the only occupationworkers considered to have the potential for dermal exposure
through the application of HC products containing D5.
The maximum AUC estimated for dermal exposure to D5 for
barbers and beauticians were 3.7 104 mg-hrs/L/day for male and
female barber or beautician for 4 days of exposure and
3.6  104 mg-hrs/L/day for a male and female barber or beauti-
cians exposed for 5 days (Table 10). The maximum AUC estimates
from inhalation exposure to D5 was 2.4  104 mg-hrs/L/day for a
barber or beautician (Table 10) using the parameters deﬁned in
Table 3. Workers involved in the formulation of AP/D were identi-
ﬁed as having the highest AUC values from inhalation exposure at
9.6  102 mg-hrs/L/day followed closely by working in facilities
manufacturing SC products at a value of 4.6  102 mg-hrs/L/day
and ﬁnally ofﬁce workers and workers in HC facilities had the
smallest values ranging between 3.2  10e4 mgehrs/L/day to
2.5  10e5 mg-hrs/L/day (Table 10) based on inhalation exposure.3.3.2.2. Consumers. The Monte Carlo analysis indicated that con-
sumer product use resulted in much greater exposure than that
obtained through exposure to D5 in environmental media (e.g.,
ingestion of soil, water, etc.). Therefore, the PBPK analysis for per-
sonal care products was limited to the products identiﬁed as
contributing the most exposure to the consumer. Products within
two orders of magnitude exposure of the product providing the
highest estimate of intake (body lotion) were selected for evalua-
tion, and included moisturizer, solid deodorant, roll-on deodorant,
sunscreen, nail care, foundation, after shave, and hair spray for
dermal exposure and soothing vapor for inhalation exposure.
Additional information is provided in detail in the supplementary
material, speciﬁcally Supplementary Tables S-1 through S-5.
The AUCs estimated for dermal exposure to D5 from the use of
HC/SC products ranged from 3.3  10e10 mg-hrs/L/day for female
exposure to shampoo products to 5.2  10e3 mg-hrs/L/day for fe-
male exposure to hand/body lotion. Model estimated AUC values
for men and women resulting from dermal exposure to HC/SC
products are reported in Table 11. Using the parameters deﬁned in
Table 6, the AUCs estimated for inhalation exposure to D5 from the
use of the selected consumer products ranged from 2.0  103 to
3.5  105 (Table 11).
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considered both inhalation of indoor and outdoor air as well as
exposure to D5 in environmental media (e.g., ingestions of soil,
water, food). Exposure to environmental mediawas also considered
for subsistence ﬁshermen where the consumption of ﬁsh was
assumed to be the main source of protein. The mean reported oral
intake of D5 determined from the MC analysis ranged from
0.005 mg/kg/day for males and females in the general public ages
60 and older to 0.008 mg/kg/day for male and female subsistence
ﬁshermen ages 12e19 years of age. The 90th percentile of oral
intake to D5 was approximately 0.011 mg/kg/day for males in the
general public or subsistence ﬁsherman 20e59 years of age.
The AUCs estimated following inhalation exposure to D5 for the
general public ranged from 5.6  106 to 5.8  106 mg-hrs/L/day
for outdoor air (Table 12). The AUC estimated due to exposure to an
indoor air concentration of 34.5 mg/m3 was approximately of
4  104 mg-hrs/L/day and when the value of 393 mg/m3 was used
as the indoor air concentration, the estimated AUC ranged from
4.4 103 to 4.6 103 mg-hrs/L/day. The mean AUCs for exposure
from food, water and soil ranged from 1.7  107 to 3.0  107 mg-
hrs/L/day, and the 90th percentiles ranged from 2.8  107 to
4.0  107 mg-hrs/L/day (Table 13).
3.4. Risk characterization
As noted previously, for this assessment, rather than attempting
to derive uncertainty factors that may be used by the various reg-
ulatory agencies and programs (i.e. Health Canada, REACH, SCCS,
OSHA, USEPA) to adjust the POD for low-dose extrapolation, a
comparison of the internal dose metric associated with the POD to
the internal dose metric estimated for each exposure scenario was
conducted to developMOS. The use of theseMOS removes the need
to consider various uncertainty factors that may be applied across
various regulatory agencies globally.
3.4.1. Occupational exposure
For inhalation exposures, seven types of workers (Table 14) were
considered for which air concentrations from the workplace had
beenmeasured. For workers in the dry cleaning industry, MOSwere
approximately 5500 to 9500; indicating that exposure to D5 as
described for these workers would not pose a hazard to health. For
workers in facilities that produced D5 or manufactured consumer
products containing D5, the estimated AUCs were highest for the
workers involved in the production of antiperspirants, and,
consequently, the lowest MOS was associated with antiperspirant
production workers, in particular men. Comparison of the AUC for
this worker to the BMDL10 resulted in an MOS of approximately
350. Therefore, based on the fact that the MOS is greater than 30
(the highest anticipated factor for noncarcinogenic effects) occu-
pational exposures to D5 are deemed acceptable and would not be
expected to pose a signiﬁcant hazard to humans.
For barbers and beauticians, it was assumed that some hair
product would be used approximately every 27e30 min during the
work day with the hands being exposed. The MOS determined for
any of these scenarios, either by the inhalation pathway (Table 13)
or the dermal pathway (Table 13), were approximately 78,000 orTable 12
Area under the curve (AUC): Inhalation e general public.
Ages Male
Outdoor Indoor
0.5 mg/m3 34.5 mg/m3 393 mg
19e59 years 5.8  106 4.0  104 4.6  1greater, when the AUCs were compared to the BMDL10, indicating
that occupational dermal exposures to D5 in these professions does
not pose a signiﬁcant hazard to human health. Finally, potential
exposure to D5 through indoor air for ofﬁce workers was evaluated
at three concentrations of D5 (9.7, 39, 120 mg/m3) and even at the
highest concentration simulated the MOS for ofﬁce workers was
>14,000 (Table 13).
3.4.2. Consumer products exposure
AUCs were estimated for average usage scenarios of consumer
products providing the greatest potential for exposure (Table 15) as
identiﬁed based on the results of the Monte Carlo analysis. Expo-
sure was assumed to occur via inhalation and dermal routes for all
products.
The smallest MOS for AP/Ds was 2300 and was based on inha-
lation exposure from the use of roll-on products in women, when
the AUCs estimated for each type of AP/D resulting from inhalation
or dermal exposure were compared to the AUC for the BMDL10. The
smallest MOS for dermal exposure was 2500 and was based on the
use of aerosol products by women. However, because the MOS for
either is greater than 1000, it is not anticipated that any of the
inhalation or dermal exposures resulting from typical consumer
usage of AP/Ds would pose a hazard.
For HC/SC products, one inhalation exposure scenario for all HC/
SC products was considered for female and male consumers
(Table 15). Maxim (1998) estimated a single air concentration that
was assumed to be representative of inhalation exposure to both
HC and SC products. Comparison of the estimated AUC associated
with a 10 min exposure to this air concentration (0.178 ppm D5) to
that associated with the BMDL10, resulted in a MOS of 22,000 in
women and an MOS of 42,000 in men. The estimated MOS indi-
cated that exposure to D5 by this route would not pose a signiﬁcant
health hazard.
For dermal exposure to HC/SC products, multiple exposure
scenarios were considered related to average application rates and
usage frequencies for multiple hair care and skin care products.
Comparisons of the AUCs associated with exposure to one of
seventeen HC/SC products to the AUC associated with the BMDL10
resulted in MOS of approximately 880 or greater (Table 15). The
lowest MOS (880) was associated with hand and body lotion usage
in women. Although slightly less than 1000, these MOS are likely
overestimates in that estimation of the AUC did not consider the
duration of exposure over a lifetime. For example, some products,
such as body lotion, may be used beginning in childhood or infancy
and continuing throughout adulthood, while others may only be
used during adult years. The estimated AUCs were for an average
daily exposure and not an average daily lifetime exposure. There-
fore, dermal exposure to D5 from the usage of HC/SC products
would not be expected to pose a signiﬁcant health hazard.
3.4.3. General public exposure
For purposes of this assessment, the general public was
considered to be individuals who could be exposed to levels of D5 in
outdoor or indoor air or through environmental media (food, water
and soil). A value of 35.4 mg/m3 was identiﬁed as representative of
the indoor air concentration to which an individual would beFemale
Outdoor Indoor
/m3 0.5 mg/m3 34.5 mg/m3 393 mg/m3
03 5.6  106 3.8  104 4.4  103
Table 13
Margins of safety (MOS): Oral exposure for the general public and subsistence ﬁshermen.
Gender Age group General public Subsistence ﬁshermen
Exposure (mg/kg body weight/day) AUC (mg-hr/L/day) MOS LED10e Exposure (mg/kg body weight/day) AUC (mg-hr/L/day) MOS LED10e
Mean Exposure
Female 12e19 years 0.007 2.1  107 19,000,000 0.008 2.3  107 19,000,000
20e59 years 0.006 1.9  107 23,000,000 0.006 2.0  107 21,000,000
60 and older 0.005 1.7  107 15,000,000 0.006 3.0  107 24,000,000
Male 12e19 years 0.007 2.3  107 21,000,000 0.008 2.3  107 20,000,000
20e59 years 0.006 2.1  107 24,000,000 0.007 2.1  107 22,000,000
60 and older 0.005 2.1  107 27,000,000 0.006 1.8  107 21,000,000
90th Percentile of Exposure
Female 12e19 years 0.011 3.3  107 14,000,000 0.010 3.2  107 14,000,000
20e59 years 0.010 3.4  107 13,000,000 0.010 3.2  107 14,000,000
60 and older 0.009 3.3  107 14,000,000 0.009 2.8  107 16,000,000
Male 12e19 years 0.013 4.0  107 11,000,000 0.013 3.9  107 11,000,000
20e59 years 0.011 3.7  107 12,000,000 0.011 3.6  107 12,000,000
60 and older 0.009 3.1  107 15,000,000 0.009 2.9  107 15,000,000
Table 14
Margins of safety (MOS): Occupational inhalation exposure.
Worker AUC (mg-hr/L/day) MOS
Men Women Men Women
Barbers and Beauticians
5 days 3.6  104 3.6  104 92,000 160,000
4 days 3.7  104 3.7  104 90,000 156,000
Inhalation
Antiperspirant 9.6  10-2 9.4  10-2 350 600
Skin Care 4.6  10-2 4.5  10-2 740 1280
Hair Care 8.6  10-5 8.5  10-5 393,000 679,000
Dry Cleaner 6.1  10-3 6.0  10-3 5500 9500
Silicone 2.8  10-3 2.7  10-3 12,200 21,000
Barbers and Beauticians 2.4  10-4 2.4  10-4 138,000 239,000
Ofﬁce Worker:
9.7 mg/m3 2.6  105 2.5  105 178,000 185,000
39 mg/m3 1.0  104 1.0  104 44,000 46,000
120 mg/m3 3.2  104 3.1  104 14,300 15,000
Table 15
Margins of safety (MOS): Exposure from selected consumer products.
Product AUC (mg-hr/L/day) MOS
Men Women Men Women
Dermal
Solid Deodorant 6.0  104 4.1  104 7600 11,200
Roll-on Deodorant 1.2  103 6.0  104 3800 7600
Aerosol Deodorant 5.3  104 1.8  103 8600 2500
Hair Spray (aerosol) 2.3  105 2.3  105 203,000 199,000
Hair Spray (pump) 3.3  105 3.4  105 140,000 137,000
Moisturizer 1.1  103 1.1  103 4300 4200
Foundation N/A 1.4  104 N/A 32,000
Hand/body Lotion 5.0  103 5.2  103 920 880
Sunscreen 7.0  105 6.5  105 66,000 71,000
Nail Care N/A 3.6  107 N/A 1.3  107
After-Shave Gel 9.8  105 N/A 47,000, N/A
Inhalation
Solid Deodorant 1.2  104 2.4  104 37,000 19,000
Roll-on Deodorant 1.0  103 2.0  103 4400 2300
Aerosol Deodorant 4.0  104 7.7  104 11,500 5900
Hair Spray (aerosol) 1.1  104 2.1  104 42,000 22,000
Hair Spray (pump) 1.1  104 2.1  104 42,000 22,000
Moisturizer 1.1  104 2.1  104 42,000 22,000
Foundation N/A 2.1  104 N/A 22,000
Hand/body Lotion 1.1  104 2.1  104 42,000 22,000
Sunscreen 1.1  104 2.1  104 42,000 22,000
Nail Care N/A 2.1  104 N/A 22,000
After-Shave Gel 1.1  104 N/A 42,000 N/A
Soothing Vapor 3.5  105 3.5  105 131,000 131,000
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the typical exposure to D5 in outdoor air to estimate D5 exposure for
the general public. The MOS determined for indoor and outdoor
inhalation using these estimates for men, women and children
residents were all greater than 11,000 (Table 16). In addition, a
conservative upper bound on the indoor air of 393 mg/m3, identiﬁed
by Health Canada (2008) representing the 90th percentile from all
available indoor air concentrations was considered. The MOS's
calculated for continuous exposure to this upper bound was 1000
for males and 1050 for females. All estimates of inhalation exposure
for the general public were estimated under the assumption that a
personwould be indoors 24 hours per day or outdoors 24 hours per
day. This bounds the potential for exposure with outdoor exposure
representing the minimum and indoor exposure representing the
maximum, while the exposure from being present indoors and
outdoors during the day falls somewhere between.
Intakes of 0.005e0.0076 mg/kg body weight/day were esti-
mated to represent the intake resulting from consumption of D5
from food, water and soil combined. These intakes also include D5
from antifoam used in processing of food, and the consumption of
D5 from the use of lipstick. The MOS determined for the mean oral
consumption for men, women and teens in both the general public
and the subsistence ﬁshermen population were all greater than
15,000,000 (Table 16). In addition, an upper bound using the 90th
percentile of consumption of 0.008e0.013 mg/kg/day resulted in
MOS values of greater than 11,000,000.4. Discussion
As with any exposure assessment, a number of assumptions
must be made and judgment used when selecting values for pa-
rameters, such as the body weight, or the duration of exposure, etc.
This introduces uncertainty into the assessment. Most parameter
estimates used in the PBPK analysis were based on the average,
mean, or midpoint in a range of values for that parameter. Since
means are measurements of central tendency, there are values for
those parameters both larger and smaller than the ones used.
Different choices for these parameters could result in larger/smaller
estimates of exposure. Depending on the magnitude of the differ-
ences between the upper bound or lower bound for a parameter
and the median, it is possible that with the interactions of several
parameters, a signiﬁcant difference in the estimated dose metrics
may be observed if upper bounds were considered, as is the case
also with the lower bounds. The difference between the mean and
the 95th percentile was less than an order of magnitude
(Supplementary table S-13b) in all cases. Therefore, if the upper
Table 16
Margins of safety (MOS): Inhalation exposure for the general public.
Residential Indoor (34.5 mg/m3) Indoor (393 mg/m3) Outdoor (0.5 mg/m3)
AUC (mg-hr/L/day) MOS LED10 AUC (mg-hr/L/day) MOS LED10 AUC (mg-hr/L/day) MOS LED10
Male Female Male Female Male Female Male Female Male Female Male Female
19e59 years 5.8  106 3.8  104 11,500 11,900 4.6  103 4.4  103 1000 1050 5.8  106 5.6  106 790,000 820,000
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should increase the exposure by nomore than a factor of 10. On this
basis, the uncertainty in dose metrics is not considered to be
signiﬁcant.
The different compartmental structures in various PBPK models
produced challenges when extrapolating between rodents to
humans for risk assessments. To overcome these difﬁculties, a
common model structure with consistent parameters between
cyclic siloxanes, routes and species was developed to simulate ex-
posures to these siloxanes. This multi-purpose siloxane model was
used for this risk assessment (McMullin et al., 2015).
D5 has an unusual set of physical chemical properties, including
low blood: air and high fat: blood partitioning. These characteristics
lead to exhaled breath and tissue time-course concentration pro-
ﬁles that could not be described without kinetically distinct storage
compartments within these tissues that account for tissue-lipid
fractions where cyclic siloxanes are transferred to these compart-
ments and slowly released from these compartments into the
blood. The process of ﬁtting a PBPK model to the rat inhalation
studies with D5 required two deep-tissue compartments in the lung
and liver to account for this kinetic behavior (Reddy et al., 2008).
Although adequate for modeling this kinetic behavior of D5, the
model description of these deep compartments as well-deﬁned
compartments equivalent to the percentages of lipid within a tis-
sue is a simpliﬁed representation of the physiological distribution
of lipids within these tissues. Similarly, fat was represented as two
distinct diffusion limited fat compartments, diffuse and distributed
fat.
The blood description in the model also includes diffusion
limited deep compartments in the arterial and venous blood similar
to the liver and lung (Reddy et al., 2008). The kinetic behavior of
cyclic siloxanes in the blood over multiple day exposures in the rat
required an additional description where a portion of D5 in the
blood is sequestered as a bound, unavailable pool of D5, resulting in
both free and bound D5 represented in the experimentally
measurable blood compartment (Andersen et al., 2001; Reddy
et al., 2003, 2007). This blood compartment is modeled as a
portion of D5 bound to blood lipids that were formed by transport
of a mobile lipid pool from a shallow-liver compartment to blood
and from blood to the diffuse-fat compartment. Conceptually, this
compartment likely represents the production and transport of
possibly chylomicron-like structures that carry D5 in the particle to
fat stores in the body without allowing D5 to be available to the
blood. Although themodeling of the kinetic data drove thesemodel
descriptions of the behavior of D5, the validity of these model as-
sumptions and the associated model derived parameters have yet
to be experimentally evaluated.
Based on a variety of data following dermal exposures from
in vitro and in vivo human skin studies and in vivo rodent studies,
the skin compartment in the human siloxane model described
uptake and evaporation from the skin assuming a two compart-
ment model that includes a skin surface axilla and a deep tissue
storage compartment likely representing the stratum corneum that
slowly releases D5 into the viable epidermis and bloodstream upon
termination of exposure (Reddy et al., 2007). In addition to evap-
oration of D5 from the skin surface following application, the modelalso describes diffusion of D5 from the deep compartment back to
the surface followed by evaporation from the skin. While this
description was essential to accurately describe the time-course
behavior of D5 following dermal application, this process for D5 is
still not well understood. Additionally, the model parameters for
dermal absorption were set using data from axilla skin. Axilla skin
absorbs chemicals more rapidly that other skin areas. It is possible,
therefore, that model predictions of internal dose following dermal
absorption could be overestimated (Reddy et al., 2007).
A general uncertainty that would apply to all populations and
scenarios is the choice of the body weight to use in the PBPK
modeling could also introduce some uncertainty. We chose to use
the US average body weight but as a check of the effect of body
weight on the PBPK model results, we also ran the model using a
body weight of 60 kg which is the recommended body weight in
the SCCS (2012) guidance. This change in the body weight, without
changing the application rates or concentrations of D5 in the
products, increased the estimated PBPK dose metrics of no more
than a factor of 2.
4.1. Occupational
The median number of years worked was used to adjust the
lifetime occupational exposure (results in factors of 0.136 for males
and 0.08 for females applied to the average AUC). It is possible that
a worker could work more than the median number of years at the
same job. For example, if a person worked 45 years at the same
occupation with the same exposure pattern, the estimates of
exposure would be 5 to 7 times higher than predicted using a
median value.
The average air concentration of D5 for the workers in HC
product plants was obtained from a single set of 16 personal time-
weighted samples taken in one plant. Similarly, the average air
concentration of D5 for workers in personal care production plants
was also obtained from a single set of 16 personal time-weighted
average samples taken in one plant. No information is given
about the variation in the samples. Without additional information,
it is impossible to predict whether the estimates of inhalation from
HC/SC products over or underestimates the exposure.
4.2. Consumers
For dermal exposure of consumers not all AP/Ds or HC/SC
products contain D5, although this assessment assumed they do.
This assumption will overestimate the exposure for exposure from
AP/Ds and HC/SC products, if a personmore typically used products
that did not contain D5. This would result in an overestimation of
the dermal exposure to D5 in AP/Ds.
Another uncertainty in consumer dermal exposure is using the
most conservative estimate of exposure and therefore the highest
internal dosemetric using the PBPKmodel. The data for conditioner
products were used because it was the HC product that would
result in the highest exposure to D5 when the application rate, the
percentage of D5 in the product and the deposition and residue
fractions were considered. This would be considered a conservative
but not representative exposure for HC products because the
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product considered and approximately 60 times higher than
shampoo (the most used HC product).
For consumer inhalation exposure not all AP/Ds or HC/SC
products contain D5, although this assessment assumed they do.
This assumption may overestimate the exposure for exposure from
AP/Ds and HC/SC products. The inhalation values for the consumer
using antiperspirants or deodorants were calculated from the
measurements taken in a single unpublished study in which only
two sets of samples were taken for each type of antiperspirant (roll-
on, solid, and aerosol). This study used one brand of antiperspirant
and the measurements were taken in a 30 m3 roomwith the vents
sealed to prevent air exchange. The study did not report the amount
of D5 in the products being applied. The authors of the study state
that they expected the exposures measured would represent the
high-end of exposure due to the study design because: the room
was sealed to air-exchange unlike most bathrooms which have an
exhaust fan or window; a single brand of each type of antiperspi-
rant was used. Different formulations of antiperspirant could
contain ingredients that could retard or enhance the evaporation of
D5; and the percentage of D5 used in the product may not have
been the same as that assumed for today's AP/D products. This
would result in an overestimation of the inhalation exposure to D5
in AP/Ds.
Other uncertainties include that inhalation values for the HC/SC
products were also calculated from a single unpublished study in
which 6 personal monitoring samples were taken for consumers
using hair products containing D5. No information was available
about the ventilation of the room, the size of the room, the exact
products being used or the amount of D5 in those products. Only
the time-weighted average of the samples was available. Without
additional information, it is impossible to predict whether the es-
timates of inhalation from HC/SC products over- or underestimates
the exposure.
Recently, the Scientiﬁc Committee on Consumer Safety (SCCS,
2015) provided an opinion on the safety of D5 in consumer prod-
ucts, estimating MOS of less than 100. In contrast to the current
assessment, SCCS relied upon PODs observed following oral or
inhalation subchronic exposure to D5 (90 days) that may not be
considered adverse or directly related to exposure. SCCS (2015)
relied upon changes in liver weights observed following oral
exposure to D5, in the absence of histopathological changes or
changes in two or more liver enzymes as per USEPA (2002) Health
Effects Division Guidance and noted by SCCS (2015). SCCS (2015)
further notes the uncertainty as to whether these effects are
adverse or adaptive.
Following inhalation exposure, SCCS (2015) relied upon end-
points associated with local toxicity in the lung observed following
exposure to higher concentrations. Dekant et al. (2015) note that
the physicochemical properties of D5 limit the maximum vapor
exposure concentrations achievable in inhalation exposures
(Burns-Naas et al., 1998) and results obtained in studies using
higher concentrations of D5 in air have to be evaluated with caution
due to the potential formation of aerosols and associated issues
with doses delivered. SCCS (2015) further noted that the histo-
pathological changes observed both in the lung and the nasal cavity
of rats exposed to the high concentrations of D5 may be due to the
localized irritation from aerosol deposition and were not consid-
ered as systemic toxicity of the test substance.
The difference in PODs combined with a lack of incorporation of
a PBPKmodel to estimate a systemic dose and consideration of only
the maximum concentration of D5 as representative of the con-
centration in products resulted in the estimation of smaller MOS.
Longer term studies with D5 do not provide results that support
that the endpoints relied upon by SCCS (2015) would be consideredadverse (Dekant et al. 2015). The use of a POD from a chronic study,
in combinationwith Monte Carlo analyses and a PBPKmodel, allow
for a comparison based on an internal dose metric (decreasing the
uncertainties with route-to-route extrapolation) and considering
the distribution of potential parameters in estimating exposure.
The current approach for estimating anMOS should incorporate the
most available science and be more representative of population
exposure.4.3. General public
Inhalation exposures to the general public were assumed to be
for a lifetime. These values were not adjusted for the length of
residency. This would overstate the risk by a factor of 8.3 to 2.3
based on the median and 95th percentile of the residency time
being 9 years and 30 years, respectively.
The migration factor of 0.0046% was based on results from an
experiment on the migration of siloxanes from silicone rubber
products into milk, formula and liquid dietary simulants (Zhang
et al., 2012). Concentrations of D5 were determined to range from
0.5 to 269 mg/g of in baby bottle nipples with a median value of
4 mg/g. However, due to the irregular shape of the silicone nipples,
migration tests were performed using silicone cake pans, which
was demonstrated to be an appropriate surrogate for the nipples.
These cake pans had an average concentration of D5 of 3451 mg/kg
e about 13 times higher than the largest value that was seen in
baby bottle nipples. Migration from food containers was assumed
to be a per day amount but there is little evidence that this amount
could be repeatedly extracted from the same product or that a new
product would be used each day. Therefore, this is a very conser-
vative estimate of the daily exposure and would provide an over-
estimation of D5 exposure.
It was also assumed that 50% of all food consumed from the
general public would contain antifoam, which is a very conserva-
tive estimate as antifoam is only contained in some processed food
and is excluded from use in milk and milk products. This assump-
tion would overestimate the amount of antifoam consumed from
the general public.
MOS's were estimated for oral intake only for teens and adults.
The results from the Monte Carlo analysis indicate oral intakes in
children are up to 10 times higher than intakes estimated for adults
(Supplemental Tables S12a and S13a). However, the large MOS
values computed for teens and adults (Table 13) would suggest that
even for children, the MOS values should be greater than 1 million.5. Conclusions
Based on the global approaches for conducting risk assessments,
it is anticipated that any MOS greater than 1000 indicates no sig-
niﬁcant risk of adverse effects. Depending upon the regulatory
body, a MOS of greater than 100 may be acceptable. MOS for three
scenarios were less than 1000 (Occupational inhalation of D5 in the
production of antiperspirants, (MOS ¼ >350), Occupational: Inha-
lation of D5 in the production of skin care products, Consumers: Use
of body lotion (MOS ¼ 880). While there is some uncertainty
remaining for the human relevance of the endpoint that is relied
upon for the MOS (possible rat-speciﬁc and rat strain-speciﬁc in-
crease in the development of spontaneous adenocarcinomas), the
MOS results are large enough to increase conﬁdence that the con-
centrations of D5 evaluated for this assessment in consumer
products, the workplace and the environment suggest no signiﬁ-
cant risk of adverse effects.
A. Franzen et al. / Regulatory Toxicology and Pharmacology 74 (2016) S25eS43S42Appendix A. Supplementary data
Supplementary data related to this article can be found at http://
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